In the Coming Year We Should Abandon Interferons and Glatiramer Acetate as First Line Therapy for MS: Commentary

Multiple Sclerosis - United States
doi 10.1177/1352458512470507
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

SAGE Publications

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy